Pneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International Experience

Солошенко, М. А.; Алексеева, Е. И.; Бзарова, Т. М.; Исаева, К. Б.; Денисова, Р. В.; Ломакина, О. Л.; Kashchenko, E; Карасёва, А. В.

doi:10.15690/vsp.v16i1.1691

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Дети с ЮИА были разделены на 2 группы: 25 пациентов на терапии метотрексатом, 25 -этанерцептом, и 50 -в фазе обострения (25 впоследствии был назначен метотрексат, 25 -этанерцепт). По результатам исследования, выявлено, что пациенты с ЮИА, вакцинированные 13-валентной пневмококковой конъюгированной вакциной, имели удовлетворительный иммунологический ответ вне зависимости от фазы заболевания и противоревматической терапии, включая метотрексат и этанерцепт [40].…”

Section: вакцинация против сезонного гриппаunclassified

Effectiveness and Safety of Vaccination in Patients with Juvenile Idiopathic Arthritis

Фридман¹,

Lyubimova

Kostik

et al. 2021

Pediatr. farmakol.

View full text Add to dashboard Cite

Background. Vaccination is the most effective method for reducing morbidity, disability, mortality from of various infections. However, there was a view for a long time that vaccines are ineffective and unsafe to use in people with rheumatological diseases, including juvenile idiopathic arthritis (JIA). Objective.The aim of the study is to analyze literature data on safety and efficacy of vaccination for JIA patients with live and non-live vaccines.Methods: literature analysis was based on data from medical databases PubMed and Google Scholar.Results. Both live and non-live vaccines are safe and immunogenic enough for children with JIA. Most studies confirm vaccination efficacy in patients with JIA when using glucocorticosteroids (GCS) and methotrexate, while therapy with disease-modifying antirheumatic drugs (DMARD) can reduce antibody titers over time. In general, antibodies levels preservation in previously vaccinated children with JIA is less than in global population. This indicates the need to administer booster doses for such patients. No adverse effects on the course of primary disease after vaccination and no post-vaccine complications were revealed.Conclusion. Vaccination of patients with JIA should be performed with reference to the therapy that the patient already receives, under the control of antibodies level. Booster doses should be implemented in case of titers decrease below the protective levels.

show abstract

Section: вакцинация против сезонного гриппаunclassified

Effectiveness and Safety of Vaccination in Patients with Juvenile Idiopathic Arthritis

Фридман¹,

Lyubimova

Kostik

et al. 2021

Pediatr. farmakol.

View full text Add to dashboard Cite

show abstract

“…Иные критерии частоты заболевания детей респира торными инфекциями выделяют для детей, посещающих дошкольные образовательные учреждения, такие как детские сады, развивающие центры. У эти х пациентов возрастает риск инфицирования при часты х контактах с другими детьми, они могут переносить более 6 респира торных эпизодов в год, из ни х 4 и более раз эти заболе вания могут протекать тяжелее, чем у и х сверстников, не посещающих образовательные учреждения [17,7]. Вместе с тем, самый высокий уровень респираторных заболе ваний регистрируется у детей дошкольного и младшего школьного возраста в течение первого года посещения образовательных учреждений [18].…”

unclassified

Modern view on a problem «children with recurrent infections» (frequently ill children) and their immune status

Казумян

Vasilenok

Теплякова

2018

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

The article presents the review of the domestic and international researches devoted to one of the most «problem» aspects of pediatrics – to patients with recurrent infections (frequently ill children) and to their immune status (an immune imbalance). Children with recurrent infections (frequently ill children) are characterized by higher, than their peers, incidence of acute respiratory infection (ARI). ARI frequency up to 8 times a year can be a normal variant at favorable course, at the same time an immune imbalance is compensated by immune system.

show abstract

Safety of antibodies to measles, mumps, rubella and diphtheria in patients with juvenile idiopathic arthritis

Фридман

Lybimova²,

Голева

et al. 2021

jour

View full text Add to dashboard Cite

Introduction. The issue of protection against vaccinepreventable diseases has acquired new urgency in connection with the decrease in the vaccination rate established by WHO against the background of the COVID-19 pandemic. This creates the conditions for outbreaks and puts patients with immunopathological diseases at particular risk, who are most often not vaccinated from the moment of diagnosis Purpose of the study – to assess the safety of specific antibodies to measles, mumps, rubella and diphtheria in children with JIA, depending on the duration of vaccination, the duration of the disease and the therapy received.Materials and methods. The vaccination rate of 171 children with juvenile idiopathic arthritis (JIA) aged (11,31±0,31 years) with the duration of the disease at the time of examination was 4,69±0,29 years, who had previously received 1-2 vaccinations against measles, mumps, rubella and 3-6 vaccinations against diphtheria. Antibodies to these infections were determined by ELISA.Results. 42.1% of children had no protective titers of antibodies to measles, 19,9% – to mumps, 9,4% – to rubella and 16,4% – to diphtheria. Among 93 vaccinated and revaccinated patients, there were no protective titers of antibodies to measles – 40,9% (38 children), mumps – 13,9% (13 people), rubella – 5,4% (5 children), and among 78 vaccinated once, respectively: measles – 43.6% (34 children), mumps – 25.6% (20 children), rubella – 14,1% (11). The level of protection against diphtheria was comparable for those who received 3-5 vaccinations. Depending on the therapy, 3 groups were identified: group 1-71 children received metatrexate and glucocorticosteroids, 2-82 children received modifying anti-rheumatic drugs (DMARD) and 18 children without this therapy (Group 3). Children of the 2nd group were on average older (12,48±0,42 years) than in the 1st and 3rd groups (10,04±0,48 and 10,96±0,96 years, respectively), they had significantly more frequent systemic variant and polyarthritis (64,6% compared to 36,6% and 16,7%, px2<0,001). The number of vaccine doses received by children in all groups before the onset of the disease did not significantly differ. >˂0,001). The number of vaccine doses received by children in all groups before the onset of the disease did not significantly differ. The average level of antibodies to measles in children of group 2 (0,32±0,07 IU/ml) was 2,8 times less than in group 3 and significantly less than in group 1 (0,78±0,16, Pt=0.009), the average value of antibodies to rubella was also significantly less in group 2 (84,48±7,34 IU/ml) than in group 1 (109,73±8,09, Pt=0,022) and in group 3 (120,01±15,42, Pt=0,042). The analysis showed that the safety of antibodies to antigens of live vaccines, especially against measles, is negatively affected by the duration of the disease and the nature of therapy. Children who received combined therapy with anti-TNF, anti-IL-6 and anti-CD-80 drugs had a longer duration of the disease (7,5±0,97 years)=0,00082 compared to those who received only anti-IL-6 (2,9±0,7 years) and antiTNF therapy (6,1±0,5 years) and with a comparable number of vaccine doses received, significantly lower average values of antibodies and a larger number of unprotected ones.Conclusions. The duration of the disease, the lack of timely age-related revaccinations, as well as the presence of combination therapy aimed at suppressing various mechanisms of the immune response in children with JIA are factors that lead to an increase in the number of unprotected from controlled infections. Immunity to measles suffers the most – 40.9% of revaccinated people are unprotected.

show abstract

Pneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International Experience

Cited by 3 publications

References 17 publications

Effectiveness and Safety of Vaccination in Patients with Juvenile Idiopathic Arthritis

Effectiveness and Safety of Vaccination in Patients with Juvenile Idiopathic Arthritis

Modern view on a problem «children with recurrent infections» (frequently ill children) and their immune status

Safety of antibodies to measles, mumps, rubella and diphtheria in patients with juvenile idiopathic arthritis

Contact Info

Product

Resources

About